The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 281.00
Bid: 282.50
Ask: 285.00
Change: -6.00 (-2.09%)
Spread: 2.50 (0.885%)
Open: 280.00
High: 287.50
Low: 280.00
Prev. Close: 287.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-Close Trading Update and Board Update

14 Jan 2021 07:00

RNS Number : 6235L
Synthomer PLC
14 January 2021
 

14th January 2021

 

Synthomer plc

 

Pre-Close Trading Update and Board Update

 

FY2020 EBITDA guidance raised c.10%; FY2020 proforma leverage expected to reduce further

Calum MacLean to stand down as Chief Executive by January 2022

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the year ended 31st December 2020 ahead of announcing the Group's Full Year results on 4th March 2021. Synthomer also announces that following 6 successful years, Calum MacLean has informed the Board that he intends to stand down as Chief Executive by January 2022.

 

Strong trading momentum across the business

 

Performance Elastomers

 

Performance Elastomers has continued to perform strongly. The positive trends experienced in our Nitrile latex business during the year continued through the final quarter of 2020 with overall performance ahead of expectations. Similarly, the conditions in our SBR latex business also continued to strengthen, with all SBR segments except paper trading ahead of the comparative period in 2019.

 

Functional Solutions

 

Functional Solutions has seen a sustained improvement in the final quarter of 2020 with our consumer facing and industrial end markets remaining strong with exception of the Oil and Gas business unit. We have seen activity levels above normal seasonal levels with overall performance ahead of expectations.

 

Industrial Specialities

 

Industrial Specialities also had a strong finish to the year, with our laminates and films business, which serves the home improvement and recreational vehicles market, trading particularly well and the division performing ahead of the equivalent period in 2019. 

 

FY 2020 EBITDA guidance raised and proforma leverage expected to reduce further

 

The combination of stronger trading across our three major divisions means that the Group now expects its 2020 EBITDA to be approximately £255m, some 10% ahead of the Company guidance of £232m provided in our trading statement of 14th October 2020.

 

The Group remains highly cash generative and now expects proforma leverage to reduce to circa 1.9x net debt to EBITDA as of 31st December 2020.

 

Outlook

 

Whilst the Group will continue to adapt its operations in response to the ongoing COVID-19 pandemic to ensure the safety of all employees, at this stage it expects no meaningful disruption to business. The Board is confident that the benefits of the OMNOVA acquisition, recent investment in new capacity, further efficiency measures, its proven growth strategy as well as continued strength in Performance Elastomers, will underpin strong EBITDA growth in 2021.

 

Board update

 

Having informed the Board that he would like to stand down as Chief Executive, Calum MacLean will leave the business by January 2022 when a successor is in place. During his 6 years as Chief Executive, Calum has driven significant change at Synthomer presiding over substantial investment and several acquisitions, notably Omnova in 2020. The process to find a new Chief Executive is underway and is expected to include both internal and external candidates. A further announcement will be made in due course.

 

Commenting Calum MacLean, Chief Executive, said:

 

"It has been a privilege to lead Synthomer for the last 6 years and I am proud of what we have achieved. With Omnova fully integrated, all core parts of the business growing and our financial outlook strong, now is the right time to hand over to someone else who can build on this exciting momentum. I look forward to welcoming my successor into the role when the time comes."

 

Commenting, Caroline Johnstone, Chair of Synthomer, said:

 

"In a very challenging year, Synthomer has delivered a strong performance, testament to the strategy that we have been consistently executing and the investments that we have made over the last five years. As we embark upon a new year and look further ahead to the future, the business is in a strong position.On behalf of the Board, I would like to thank Calum for everything that he has done to take Synthomer forward since joining at the start of 2015. His leadership and vision have transformed the business into a truly diversified, differentiated and global company. The next chapter promises to be just as exciting and the Board looks forward to working with a new Chief Executive in due course."

 

-ENDS-

 

Further information:

 

Calum MacLean, Chief Executive Officer

Steve Bennett, Chief Financial Officer Tel: + 44 1279 436211

Tim Hughes, President, Corporate Development

 

Charles Armitstead/ Matt Denham, Teneo Tel: + 44 7703 330 269/ + 44 7825 735596

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFIILIIVLIL
Date   Source Headline
9th May 20242:29 pmRNSResults of AGM
9th May 20247:00 amRNSTrading Statement - Spring 2024
1st May 20247:00 amRNSDivestment of Compounds completed
25th Apr 20244:30 pmRNSDirector/PDMR Shareholding
25th Apr 20244:20 pmRNSDirector/PDMR Shareholding
17th Apr 202410:43 amRNSTender offer results
15th Apr 20247:00 amRNSDivestment of Compounds
12th Apr 20247:00 amRNSPricing of senior notes
9th Apr 20243:47 pmRNSPre Stabilisation Notice
9th Apr 20248:09 amRNSNotice of tender offer
9th Apr 20248:09 amRNSProposed offering of senior notes
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:38 pmRNSDirector/PDMR Shareholding
28th Mar 20242:10 pmRNSAnnual Financial Report and Notice of AGM
12th Mar 20247:00 amRNSFinal Results
30th Jan 20247:00 amRNSTrading Statement
17th Jan 20242:58 pmRNSExternal Appointment
15th Nov 20237:00 amRNSTrading statement - Autumn 2023
3rd Nov 20232:54 pmRNSDirector/PDMR Shareholding
23rd Oct 20231:58 pmRNSDirector/PDMR Shareholding
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
17th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20233:13 pmRNSHolding(s) in Company - CORRECTION
16th Oct 202312:06 pmRNSHolding(s) in Company
16th Oct 202312:03 pmRNSHolding(s) in Company
16th Oct 202311:57 amRNSHolding(s) in Company
16th Oct 20237:00 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSPDMR and PCA Notification
13th Oct 20234:18 pmRNSHolding(s) in Company
13th Oct 202310:48 amRNSHolding(s) in Company
13th Oct 20237:00 amRNSResult of rump placing
12th Oct 20234:36 pmRNSResult of Equity Issue
12th Oct 202310:09 amRNSHolding(s) in Company
11th Oct 20239:39 amRNSHolding(s) in Company
11th Oct 20237:00 amRNSPDMR PCA Notification
10th Oct 20233:04 pmRNSHolding(s) in Company
10th Oct 202310:26 amRNSHolding(s) in Company
10th Oct 202310:26 amRNSHolding(s) in Company
9th Oct 20233:08 pmRNSHolding(s) in Company
9th Oct 20239:44 amRNSHolding(s) in Company
6th Oct 20231:56 pmRNSHolding(s) in Company
6th Oct 20238:53 amRNSHolding(s) in Company
5th Oct 20232:40 pmRNSDirector/PDMR Shareholding
5th Oct 202312:27 pmRNSHolding(s) in Company
2nd Oct 20232:22 pmRNSHolding(s) in Company
28th Sep 20237:00 amRNSAdmission of Nil Paid Rights
27th Sep 20237:00 amRNSDespatch of PALs
26th Sep 20237:00 amRNSCapital Reorganisation
25th Sep 20231:58 pmRNSResults of General Meeting
22nd Sep 20233:21 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.